Search

Jigucao capsules, consisting of ten kinds of traditional Chinese medicines: Panax notoginseng, Artificial bezoar, Maojigucao, Gardeniae fructus and Artemisiae Scopariae Herba, possesses the effects of soothing the liver and disinhibiting the gallbladder, clearing heat and removing toxin. Jigucao capsules is widely used in the treatment of cholecystitis in clinical practice. Relevant researches have shown that Jigucao capsules alone or in combination with Western medicine could improve the clinical signs and symptoms of patients with cholecystitis, with significant clinical efficacy. In order to enable clinicians in primary medical institutions to use Muxiang Shunqi pills more scientifically and safely, Expert Consensus on Jigucao Capsules in the Treatment of Cholecystitis in Primary Care was jointly drafted by relevant experts from Beijing Friendship Hospital, Capital Medical University, and Clinical Research on Traditional Chinese Medicine Branch of China International Exchange and Promotive Association for Medical and Health Care. Based on the questionnaire survey and literature review of clinical experts, the consensus adopts the GRADE system and fully combined with expert experience to form recommendations or consensus recommendations through the Nominal Group Technique. This consensus clarifies the indications, key points of diagnosis and treatment, usage and dosage, course of treatment, and safety of Jigucao capsules in the treatment of cholecystitis, which is suitable for Chinese clinicians, Western clinicians, general clinicians and clinical pharmacists in hospitals of various levels. [ABSTRACT FROM AUTHOR]

Muxiang Shunqi pills, consisting of eleven traditional Chinese medicines: Aucklandiae radix, Amomum aurantiacum H. T. Tsai Et S. W. Zhao, Cyperi rhizome, Arecae semen, licorice, Citrus reticulata, Magnolia officinalis rehd Et Wils, Aurantii fructus, Atractylodes lancea ( Thunb. ) Dc., Citri reticulatae pericarpium viride and Zingiber officinale roscoe, possesses the effects of promoting Qi circulation to remove dampness, and strengthening the spleen and stomach. Muxiang Shunqi pills is widely used in the treatment of gastroesophageal reflux disease. A large number of studies have confirmed that Muxiang Shunqi pills can effectively relieve the symptoms of gastroesophageal reflux disease, with significant therapeutic effect, whether it is used alone or combined with other Chinese and Western medicines. In order to enable clinicians in primary medical institutions to use Muxiang Shunqi pills more scientifically and safely, Expert Consensus on Muxiang Shunqi Pills in Treatment of Gastroesophageal Reflux Disease in Primary Care was jointly drafted by relevant experts from Beijing Friendship Hospital, Capital Medical University, and Clinical Research on Traditional Chinese Medicine Branch of China International Exchange and Promotive Association for Medical and Health Care. Based on the questionnaire survey and literature review of clinical experts, the consensus adopts the GRADE system and fully combined with expert experience to form recommendations or consensus recommendations through the Nominal Group Technique. This consensus clarifies the indications, key points of diagnosis and treatment, usage and dosage, course of treatment, drug combination, and safety of Muxiang Shunqi pills in the treatment of gastroesophageal reflux disease, which is suitable for Chinese clinicians, Western clinicians, general clinicians and clinical pharmacists in hospitals of various levels. [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)